Business
RETRANSMISSION: Manganese X Appoints Globally Renowned Air Infection Solutions Specialist to Subsidiary Advisory Board
Montreal, Quebec--(Newsfile Corp. - October 6, 2020) - Manganese X Energy Corp. (TSXV: MN) (F...
About this update from Manganese X Energy Corp.
[{"type":"text","content":"RETRANSMISSION: Manganese X Appoints Globally Renowned Air Infection Solutions Specialist to Subsidiary Advisory BoardMontreal, Quebec--(Newsfile Corp. - October 6, 2020) - Manganese X Energy Corp. (TSXV: MN) (FSE: 9SC2) (OTC Pink: MNXXF) (\"Manganese X\" or the \"Company\"), through its subsidiary, recently acquired a U.S. patent that provides for a system and method for air purification and disinfection. The company will be expanding on this timely and relevant technological theme and is pleased to welcome Lino G. Morris, a globally recognized expert in air quality systems and management.Martin Kepman, CEO of Manganese X comments, \"Lino, as he is known worldwide, is held in extremely high regard as a leading designer and developer of innovative scientific and healthcare solutions, biological manufacturing operations and systems design. He brings a unique blend of talents in both technology and management demonstrated in a wide range of projects worldwide in the sciences, product research & development, manufacturing and implementation. Lino has a reputation with governments and companies in a dozen countries for rapidly overcoming all obstacles and delivering on commitments.\"For many years starting in 1971, Lino was the Responsible Head and an owner of FDA licensed facilities that produced both medical products for human use and ran R&D operations to develop and manufacture a range of both medical therapeutic use and medical laboratory testing products for a wide variety of the major pharmaceutical companies. He grew the original USA facilities into production operations in several other countries and expanded his markets to a wide range of international markets. He is currently the CEO of the PureBiotics® Group which started investigating the applications of probiotics for external healthcare applications in 2007 and in 2008 acquired the exclusive rights for a European line of probiotic products for North America and a range of other countries and for several specific applications and expanded research for 'stabilized external use probiotics for environmental control applications.' These \"StaBiotics\"® products proved to be a major break-through and a truly \"disruptive technology\" with applications that became proven for a wide range solutions from the medical field (where it can reduce the risk of...